https://www.live-feeds.com/feed/inside-moderna-and-merck-s-cancer-vaccine-triumphContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/inside-moderna-and-merck-s-cancer-vaccine-triumphhttps://www.live-feeds.com/feed/inside-moderna-and-merck-s-cancer-vaccine-triumph#u50814Fri, 28 Aug 2026 10:35:19 +0000Moderna and Merck's cancer vaccine, using mRNA technology, has shown effectiveness in reducing melanoma recurrence risk in a late-stage trial, leading to increased investor confidence.Why it mattersThe vaccine's success could mark a significant advancement in cancer treatment, offering new hope for patients. The trial's positive results have already impacted Moderna's stock price. This development is part of a broader effort to explore mRNA technology in fighting cancer.What is confirmedModerna and Merck's cancer vaccine uses mRNA technology.The vaccine has shown effec https://www.live-feeds.com/feed/inside-moderna-and-merck-s-cancer-vaccine-triumphhttps://www.live-feeds.com/feed/inside-moderna-and-merck-s-cancer-vaccine-triumph#u48512Wed, 26 Aug 2026 00:02:17 +0000Moderna and Merck's cancer vaccine, tested in a late-stage trial, has shown promise in preventing melanoma from returning. The vaccine, which uses mRNA technology, has been found to be effective in reducing the risk of cancer recurrence. The trial's positive results have led to a significant increase in Moderna's stock price.Why it mattersThe development of a cancer vaccine has been a long-standing goal in the medical community, and the success of this trial could pave the way for new treatments and potentially even preventative measures against certain types of cancer. The use